Skip to main content
For over 50 years, the potential advantages of charged particles in cancer therapy has motivated the medical community to advance the clinical application of proton therapy. It can maximize radiation dose to tumor sites, while sparing adjacent healthy tissues, and is especially effective in treating many rare cancers, especially pediatric cancers. Proton beams enter the body, releasing small amounts of energy until reaching the tumor site where the protons' maximum energy is deposited and then stops, resulting in minimal exit dose. As a result, short term and long term side effects from radiation dose to normal tissues and organs are reduced or avoided, unlike most other forms of radiation treatment. It is easy to understand why the number of proton therapy centers and patients seeking the treatment are steadily growing.
Hitachi is proud of its long history in particle beam therapy. From the national centers in Japan 20 years ago, leading up to the installation at some of the most renowned cancer centers in the United States and Japan today, Hitachi's advanced R&D teams have earned a reputation for turning challenging collaboration projects and concepts into commercial reality. Leveraging a culture that thrives on innovation and customer satisfaction, Hitachi builds each system with an unmatched dedication to quality, performance and reliability.
Hitachi was the first to bring FDA 510(k) cleared and clinically implemented spot scanning proton therapy technology to the U.S. market - today's new standard in precision PBT treatment delivery, which is also Pharmaceutical and Medical Devices Agency (PMDA) approved in Japan.* Hitachi's Discrete Spot Scanning Technology allows the most advanced treatment application of PBT, such as Intensity Modulated Proton Therapy (IMPT). In the United States, over 1,000 patients have been treated with Hitachi's industry leading, clinically proven Discrete Spot Scanning system.
* FDA 510(k) Approval No. :K073059
* PMDA Approval No.：22200BZX00124000
The treatment of moving targets affected by respiration, such as those in the lung or liver, require special care. This need has given rise to “Real-time image Gated Proton beam Therapy (RGPT) ”*1, the highly anticipated combination of Hitachi's Discrete Spot Scanning Technology and Real-time Tumor-tracking, and automated beam triggering, developed with partner Hokkaido University. As a result, this innovation is now in clinical use at Hokkaido University's PROBEAT-RT*2, achieving high dose delivery while significantly minimizing exposure to healthy tissue and organs.
*1 RGPT is granted by the Japan Society for the Promotion of Science (JSPS) through the “Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST Program),” initiated by the Council for Science and Technology Policy (CSTP)
*2 PMDA Approval No. :22600BZX00068000
Hitachi's fundamental quality standards in design and manufacturing have been continually improving clinical efficiency of its proton therapy systems, producing industry leading equipment reliability.
To attain superior uptimes, Hitachi's systems are designed with features allowing highly efficient preventative maintenance to maximize clinical system availability.
Hitachi's strong and successful proton therapy system operating experience, performing with consistently high uptime, gives us the confidence to guarantee high system availabilities from day one. In fact, Hitachi has achieved availabilities greater than 98% over multiple years at M.D. Anderson in the U.S. and at Hitachi proton therapy centers in Japan as well - due in part to the seamless teamwork between the on-site maintenance team and Hitachi's remote 24/7 365 days/year monitoring system manned by Hitachi engineers from its headquarters from Japan.
These key characteristics of Hitachi's system and operations have created a proven and stable platform, where the primary goal of Hitachi maintenance teams is to continually strive for 100% availability.
Hitachi offers an extensive variety of system configurations to meet every customer's needs, ranging from smaller single treatment room systems to larger multi-treatment room configurations. Hitachi also offers a new, compact, energy efficient synchrotron accelerator to power single and multi-room systems, with a complete selection of rotating gantries, including a full sized 360 degree gantry, a 360 degree compact gantry*1 and a partial 190 degree gantry*2.
In early 2014, Hokkaido University began treating patients on Hitachi's first compact*3 single room 360 degree gantry system, featuring two industry firsts: compact gantry mounted CBCT and Real-time Tumor-tracking. Hitachi's advanced, compact single room solution is expandable and does not require an added accelerator to power multiple rooms, and supports today's most advanced treatment application techniques, such as IMPT*4, RGPT*5 and CBCT*1,6,7.
*1 PMDA Approval No. :22600BZX00068000
*2 FDA 510(k) Approval No. :K151132
*3 30% smaller footprint compared to previous design.
*4 IMPT : Intensity Modulated Proton Therapy
*5 RGPT : Real-time image Gated Proton beam Therapy ;
Co-developed with Hokkaido University in Japan.
*6 CBCT : Cone Beam CT ; Co-developed with Hokkaido
University in Japan.
*7 FDA 510(k) Approval No. ：K152592
This website includes information intended for healthcare professionals.
Please note that all descriptions in this website conform to the Pharmaceutical and Medical Device Act in Japan as well as other laws and regulations in Japan. Model names, specifications and configurations of products in overseas market outside Japan may be different by the countries.